News | In The News | Publications

August 9, 2012
Tokai Pharmaceuticals Appoints Adrian M. Senderowicz, M.D., as Chief Medical Officer and Vice President, Medical Development

June 12, 2012
Tokai Pharmaceuticals’ Galeterone Receives Fast Track Designation From the FDA for the Treatment of Advanced Prostate Cancer

May 17, 2012
Tokai Pharmaceuticals’ Galeterone Phase 1 Data in Patients with Advanced Prostate Cancer to be Presented at ASCO Annual Meeting 2012

March 31, 2012
Tokai Pharmaceuticals’ Galeterone Well-Tolerated in Patients with Advanced Prostate Cancer; Phase 1 Data Presented at AACR Annual Meeting 2012

September 20, 2011
Tokai Pharmaceuticals Raises $23 Million in Funding; Oncology Industry Veteran Martin D. Williams Named Chief Executive Officer

November 10, 2009
Tokai Pharmaceuticals Initiates ARMOR Clinical Development Program for TOK-001; First Ever Multi-Target Investigational Drug for Prostate Cancer

May 8, 2009
Tokai Pharmaceuticals Closes $22 Million Series D Funding